Kandiah Sheetal, Altamimi Sarah, Shaeer Kristy M, Holubar Marisa, Wagner Jamie L
Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Grady Health System, Atlanta, GA, USA.
Antimicrob Steward Healthc Epidemiol. 2025 Feb 26;5(1):e68. doi: 10.1017/ash.2025.38. eCollection 2025.
The high cost of antimicrobials presents critical challenges for healthcare providers managing infections amidst the growing threat of antimicrobial resistance (AMR). High costs hinder access to necessary treatments, disproportionately affecting disadvantaged populations and exacerbating health disparities. High drug prices necessitate the use of less effective or more toxic alternatives, leading to suboptimal outcomes and prolonged hospitalizations. This, in turn, increases healthcare costs and undermines efforts to combat AMR. Equitable policies, national formularies, and cost caps for essential antimicrobials can ensure universal access to life-saving treatments and enable antimicrobial stewardship programs to ensure the best possible outcomes.
在抗菌药物耐药性（AMR）威胁日益增长的情况下，抗菌药物的高昂成本给管理感染的医疗服务提供者带来了严峻挑战。高昂的成本阻碍了获得必要治疗的机会，对弱势群体造成了不成比例的影响，并加剧了健康差距。高昂的药品价格使得人们不得不使用效果较差或毒性更大的替代药物，导致治疗效果不理想和住院时间延长。这反过来又增加了医疗成本，并破坏了对抗AMR的努力。公平的政策、国家药品目录和基本抗菌药物的成本上限可以确保普遍获得救命治疗，并使抗菌药物管理计划能够确保尽可能好的治疗效果。
